The expansion of PD1+ effector lymphocytes encourages the potential combination with lymphocyte-targeted cancer immunotherapies; on the other hand, the expansion of PD-1+ Tregs may counteract this effect and need further investigation of Treg mediated effects (Kumagai et al., 2020). The gene discussed is PDCD1; the disease is cancer.